The benefits of marginal brain therapy

See allHide authors and affiliations

Science  14 Sep 2018:
Vol. 361, Issue 6407, pp. 1084
DOI: 10.1126/science.361.6407.1084-b

Diffuse gliomas are among the most common brain tumors in adults. Surgery is often successful, but, in many patients, the tumor eventually recurs at the surgical margins. A promising drug targets certain mutationally altered metabolic enzymes in gliomas but is toxic when delivered systemically. Shankar et al. hypothesized that both problems could be addressed by applying the drug directly to the surgical margins immediately after tumor resection. They developed a diagnostic tool that can be used in the operating room to determine tumor mutation status and, hence, drug sensitivity. By studying mouse models, they found that when they injected a sustained-release formulation of the drug directly into gliomas of the appropriate genotype, the mice survived considerably longer than control mice.

Proc. Natl. Acad. Sci. U.S.A. 115, E8388 (2018).

Navigate This Article